Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery
Preoperative [18F]-FES PET/CT Imaging and Estrogen Receptor Expression Analysis in Endometriosis Surgery: This study includes preoperative \[18F\]-FES PET/CT imaging to assess estrogen receptor expression in endometriosis patients undergoing laparoscopic or robot-assisted surgery. Pain levels will be evaluated using VAS, BPI, HADS, and SF-36 scales. Immunohistochemistry and quantitative mRNA expression analysis (ESR1, ESR2, GPER) will be performed on excised lesions using Tissue Microarray. This approach aims to correlate PET/CT imaging findings with histological and molecular data, distinguishing it from standard surgical interventions.
Study summary
Diagnostic wandering is one of the characteristics of endometriosis due to great anatomical and clinical variability but also due to poorly relevant diagnostic examinations. \[18F\]-FES PET/CT could on the one hand improve diagnosis by showing greater sensitivity than MRI and on the other hand make it possible to quantify and characterize the expression of ER from diagnosis and thus helping to guide therapeutic care. We will thus attempt to correlate the intensity of \[18F\]-FES PET/CT with the expression of estrogen receptors and the intensity of pain.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
Cases:
\- Painful patients with a VAS ≥ 4 treated surgically for painful symptoms related to endometriosis;
Controls:
* Patient with a VAS \< 4 treated surgically for endometriosis in the context of infertility;
* Age \> 18 years;
* Patient who provided informed consent;
* Patients who underwent a preoperative MRI and were not contraindicated for \[18F\]-FES PET/CT;
* Patient who underwent surgery mid-cycle;
* Affiliation to a social security scheme
Exclusion Criteria:
* Patient treated for endometriosis without surgery;
* Pregnant patient
* Patient taking hormone therapy
* Menopausal patient
* Hypersensitivity to the active substance (Fluoroestradiol (18F)) or to any of the excipients
* Patient under legal protection
* Claustrophobic patient
Primary outcome measure(s)
Quantification of Estrogen Receptor Overexpression in Endometriotic Lesions Using SUV on [18F]-FES PET/CT — Preoperative assessment at mid-cycle, before surgery and without concurrent hormonal treatment. Estrogen receptor (ER) overexpression in endometriotic lesions will be assessed using the Standardized Uptake Value (SUV) on preoperative \[18F\]-FES PET/CT imaging. Each lesion's SUV will be quantified and compared within patients and between groups with high pain levels (VAS ≥ 4) and low or no pain (VAS \< 4). ER overexpression is defined as increased \[18F\]-FES uptake compared to background levels. The correlation between SUV values and pain severity will be analyzed to determine whether ER overexpression is associated with symptomatic burden. Higher SUV values indicate greater ER expression.
Trial sites (1)
Facility
City
Region
Status
Toulouse, Rangueil Hospital
Toulouse
France
Recruiting
More University Hospital, Toulouse trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
